

02 AUG 2005

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/544123
			Filing Date	August 2, 2005
			First Named Inventor	Michel SCHNEIDER
			Art Unit	TBA
			Examiner Name	TBA
			Attorney Docket Number	BR-033 PUS 01
Sheet	1	of	2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US 2002/0102217	08-01-2002	Nycomed Imaging AS	
	AB	US 5,445,813	08-29-1995	Bracco International B.V.	
	AC	US 6,139,819	10-31-2000	ImaRx Pharmaceutical Corp.	
	AD	US 6,146,657	11-14-2000	ImaRx Pharmaceutical Corp.	
	AE	US 6,221,337	04-24-2001	Nycomed Imaging AS	
	AF	US 6,280,705	08-28-2001	Alliance Pharmaceutical Corp.	

Documents  
not  
provided.  
/LHS/

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO 94/15244	08-17-1994	Sintetica S.A.		
	BB	WO 94/09829	05-11-1994	Sintetica S.A.		
	BC	WO 94/01140	01-20-1994	LINDER, Rudolf et al.		
	BD	WO 96/09037	03-28-1996	The Liposome Company, Inc.		
	BE	WO 97/29783	08-21-1997	Nycomed Imaging AS		
	BF	WO 97/40858	11-06-1997	ImaRx Pharmaceutical Corp.		
	BG	WO 98/05364	02-12-1998	Nycomed Imaging AS		
	BH	WO 99/08716	02-25-1999	Nycomed Imaging AS		
	BI	WO 99/36104	07-22-1999	Du Pont Pharmaceuticals		
	BJ	WO 02/055544	07-18-2002	Dyax Corp.		
	BK	EP 1 419 789 A2	05-19-2004	Bristol-Myers Squibb Pharma. Company		
	BL	EP 1 228 770 A1	08-07-2002	Bracco Research S.A.		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	CA	MICHEL SCHNEIDER et al: "BR1: A New Ultrasonographic Contrast Agent Based on Sulfur Hexafluoride-Filled Microbubbles" Investigative Radiology, Vol. 30, No. 8, pages 451-457, XP611270		
	CB	SIMON LOCKYER et al: "Demonstration of Flow and Platelet Dependency in a Ferric Chloride-Induced Model of Thrombosis" Journal of Cardiovascular Pharmacology, Vol. 33, No. 5, pages 718-725		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Leah Schlientz/	Date Considered	04/21/2009
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/544123
				Filing Date	August 2, 2005
				First Named Inventor	Michel SCHNEIDER
				Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	2	Attorney Docket Number	BR-033 PUS 01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CC	ERIKA BOHL KULLBERG et al: "Development of EGF-Conjugated Liposomes for Targeted Delivery of Boronated DNA-Binding Agents" Bioconjugate Chem. Vol. 13, No. 4, pages 737-743	
	CD	BRIAN C. EATOCK et al: "Numerical studies of the spectrum of low-intensity ultrasound scattered by bubbles" J. Acoust. Soc. Am., Vol. 77, No. 5, pages 1692-1701	
	CE	YEKTA OZER et al: "Influence of Freezing and Freeze-Drying on the Stability of Liposomes Dispersed in Aqueous Media, Acta Pharm. Technol., 1988, pages 129-139, Vol. 34, No. 3, pages 129-139	
	CF	MARTIN MACPINSTEN: "Surfactants and Polymers in Drug Delivery" Marcel Dekker, pages 56-60	
	CG	MATTHEW J. HASIK et al: "Evaluation of synthetic phospholipids ultrasound contrast agents", Ultrasonics, 2002, pages 973-982, Elsevier Science B.V., New York, N.Y.	
	CH	PCT Search Report for PCT/IB2004/000243, mail date 09-22-2004	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language translation is attached.

Examiner Signature	/Leah Schlientz/	Date Considered	04/21/2009
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/